Zicix (OTCMKTS:ZICX) Vs. Invitae (NYSE:NVTA) Head-To-Head Analysis
Zicix (OTCMKTS:ZICX) Vs. Invitae (NYSE:NVTA) Head-To-Head Analysis
Zicix (OTCMKTS:ZICX – Get Rating) and Invitae (NYSE:NVTA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.
Zicix(OTCMKTS：ZICX-GET Rating)和Invitae(NYSE：NVTA-GET Rating)都是小盤醫療公司，但哪一家是更好的投資？我們將根據這兩家公司的風險、機構所有權、分析師建議、收益、盈利能力、股息和估值的強弱對它們進行比較。
Analyst Ratings
分析師評級
This is a breakdown of current ratings and recommmendations for Zicix and Invitae, as reported by MarketBeat.
據MarketBeat報道，這是對Zicix和Invitae的當前評級和推薦的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zicix | 0 | 0 | 0 | 0 | N/A |
| Invitae | 3 | 9 | 0 | 0 | 1.75 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Zicix | 0 | 0 | 0 | 0 | 不適用 |
| 邀請函 | 3 | 9 | 0 | 0 | 1.75 |
Invitae has a consensus price target of $8.04, suggesting a potential upside of 168.10%. Given Invitae's higher probable upside, analysts clearly believe Invitae is more favorable than Zicix.
Invitae的一致目標價為8.04美元，暗示潛在上漲168.10%。鑑於Invitae的上行可能性更高，分析師顯然認為Invitae比Zicix更有利。
Volatility & Risk
波動性與風險
Earnings & Valuation
收益與估值
This table compares Zicix and Invitae's gross revenue, earnings per share and valuation.
此表比較了Zicix和Invitae的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zicix | N/A | N/A | N/A | N/A | N/A |
| Invitae | $460.45 million | 1.58 | -$379.01 million | ($13.84) | -0.22 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Zicix | 不適用 | 不適用 | 不適用 | 不適用 | 不適用 |
| 邀請函 | 4.6045億美元 | 1.58 | -3.7901億美元 | ($13.84) | -0.22 |
Zicix has higher earnings, but lower revenue than Invitae.
與Invitae相比，Zicix的收益更高，但收入更低。
Insider and Institutional Ownership
內部人與機構持股
88.3% of Invitae shares are held by institutional investors. 1.1% of Invitae shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Invitae 88.3%的股份由機構投資者持有。Invitae 1.1%的股份由內部人士持有。強大的機構持股表明，捐贈基金、大型基金管理公司和對衝基金相信，一家公司有望實現長期增長。
Profitability
盈利能力
This table compares Zicix and Invitae's net margins, return on equity and return on assets.
此表比較了Zicix和Invitae的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Zicix | N/A | N/A | N/A |
| Invitae | -617.65% | -39.04% | -17.75% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Zicix | 不適用 | 不適用 | 不適用 |
| 邀請函 | -617.65% | -39.04% | -17.75% |
Summary
摘要
Invitae beats Zicix on 5 of the 8 factors compared between the two stocks.
在比較兩隻股票的8個因素中，Invitae有5個勝過Zicix。
About Zicix
關於Zicix
(Get Rating)
(獲取評級)
Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.
Zicix公司通過其子公司德克薩斯移動健康公司在德克薩斯州休斯頓提供診斷醫學成像服務。它提供心臟診斷服務，包括超聲心動圖、壓力測試、頸動脈超聲以及HARTER和事件監測服務；醫療服務，如普通醫療、家庭健康患者的醫療護理、普通和移民體檢、減肥、冷激光止痛治療、物理治療和抗衰老治療；以及MRI、CT和X光服務。該公司前身為Bederra Corporation，並於2011年2月8日更名為Zicix Corporation。Zicix公司成立於1979年，總部設在德克薩斯州休斯頓。
About Invitae
關於Invitae
(Get Rating)
(獲取評級)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Invitae公司是一家醫學遺傳學公司，將遺傳信息整合到主流醫學中，以改善美國、加拿大和國際上人們的醫療保健。該公司提供各種臨牀領域的基因測試，包括遺傳癌、心臟病學、神經病學、兒科、腫瘤學、代謝疾病和罕見疾病；數字健康解決方案；以及健康數據服務。它為患者、醫療保健提供者、生物製藥公司和其他合作伙伴提供服務。該公司前身為Locus Development，Inc.，並於2012年更名為Invitae Corporation。Invitae Corporation成立於2010年，總部位於加利福尼亞州舊金山。
Receive News & Ratings for Zicix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zicix and related companies with MarketBeat.com's FREE daily email newsletter.
接受Zicix Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zicix和相關公司的最新新聞和分析師評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。